Celldex Therapeutics Stock Equity Positions Weight

CLDX Stock

USD 25.39 0.26 1.01%

Celldex Therapeutics fundamentals help investors to digest information that contributes to Celldex Therapeutics' financial success or failures. It also enables traders to predict the movement of Celldex Stock. The fundamental analysis module provides a way to measure Celldex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celldex Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Celldex Therapeutics Company Equity Positions Weight Analysis

Celldex Therapeutics' Percentage of fund asset invested in equity instruments. About 80% of global funds and ETFs carry equity instruments on their balance sheet.

Stock Percentage

% of Equities

in the fund

More About Equity Positions Weight | All Equity Analysis

Celldex Equity Positions Weight Driver Correlations

Understanding the fundamental principles of building solid financial models for Celldex Therapeutics is extremely important. It helps to project a fair market value of Celldex Stock properly, considering its historical fundamentals such as Equity Positions Weight. Since Celldex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Celldex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Celldex Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Short Term Debt	Common Stock	Intangible Assets	Current Deferred Revenue	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.98	-0.43	-0.67	0.33	0.94	0.36	0.73	0.03	0.39	0.19	0.54	0.44	0.88	0.84	-0.64	0.68	0.56	0.66	-0.53	0.67	0.61
Total Stockholder Equity	0.98		-0.43	-0.69	0.16	0.98	0.31	0.75	-0.07	0.27	0.03	0.5	0.32	0.93	0.91	-0.61	0.7	0.49	0.71	-0.57	0.74	0.69
Net Debt	-0.43	-0.43		-0.07	-0.09	-0.42	0.03	-0.23	0.13	-0.39	0.03	-0.55	-0.42	-0.15	-0.26	0.36	-0.04	0.09	-0.08	-0.03	0.02	0.07
Retained Earnings	-0.67	-0.69	-0.07		-0.06	-0.66	-0.6	-0.56	0.13	0.22	-0.08	0.06	0.11	-0.72	-0.66	0.64	-0.93	-0.76	-0.36	0.5	-0.64	-0.8
Total Liab	0.33	0.16	-0.09	-0.06		0.0	0.28	0.04	0.53	0.72	0.91	0.35	0.74	-0.05	-0.17	-0.31	0.11	0.48	-0.06	0.13	-0.19	-0.27
Total Current Assets	0.94	0.98	-0.42	-0.66	0.0		0.26	0.75	-0.17	0.16	-0.11	0.48	0.23	0.96	0.96	-0.55	0.66	0.38	0.73	-0.6	0.78	0.73
Net Receivables	0.36	0.31	0.03	-0.6	0.28	0.26		0.33	0.08	-0.02	0.29	-0.28	0.01	0.28	0.15	-0.4	0.45	0.67	-0.09	-0.55	0.09	0.23
Accounts Payable	0.73	0.75	-0.23	-0.56	0.04	0.75	0.33		-0.24	0.2	-0.06	0.34	0.21	0.74	0.68	-0.42	0.49	0.31	0.51	-0.68	0.53	0.56
Short Term Debt	0.03	-0.07	0.13	0.13	0.53	-0.17	0.08	-0.24		0.39	0.36	0.28	0.54	-0.19	-0.25	-0.02	-0.15	0.23	-0.03	0.16	-0.17	-0.3
Common Stock	0.39	0.27	-0.39	0.22	0.72	0.16	-0.02	0.2	0.39		0.45	0.68	0.79	0.05	0.01	-0.2	-0.14	0.22	0.15	0.04	-0.15	-0.31
Intangible Assets	0.19	0.03	0.03	-0.08	0.91	-0.11	0.29	-0.06	0.36	0.45		0.08	0.54	-0.13	-0.26	-0.22	0.08	0.37	-0.19	0.13	-0.24	-0.25
Current Deferred Revenue	0.54	0.5	-0.55	0.06	0.35	0.48	-0.28	0.34	0.28	0.68	0.08		0.81	0.33	0.39	-0.38	0.04	-0.01	0.3	0.04	0.09	-0.05
Property Plant Equipment	0.44	0.32	-0.42	0.11	0.74	0.23	0.01	0.21	0.54	0.79	0.54	0.81		0.09	0.07	-0.29	-0.05	0.12	0.07	0.13	-0.14	-0.27
Short Term Investments	0.88	0.93	-0.15	-0.72	-0.05	0.96	0.28	0.74	-0.19	0.05	-0.13	0.33	0.09		0.97	-0.47	0.7	0.42	0.79	-0.67	0.86	0.82
Net Tangible Assets	0.84	0.91	-0.26	-0.66	-0.17	0.96	0.15	0.68	-0.25	0.01	-0.26	0.39	0.07	0.97		-0.47	0.68	0.33	0.77	-0.54	0.85	0.8
Long Term Debt Total	-0.64	-0.61	0.36	0.64	-0.31	-0.55	-0.4	-0.42	-0.02	-0.2	-0.22	-0.38	-0.29	-0.47	-0.47		-0.66	-0.52	-0.14	0.16	-0.27	-0.34
Capital Surpluse	0.68	0.7	-0.04	-0.93	0.11	0.66	0.45	0.49	-0.15	-0.14	0.08	0.04	-0.05	0.7	0.68	-0.66		0.72	0.48	-0.25	0.73	0.8
Short Long Term Debt	0.56	0.49	0.09	-0.76	0.48	0.38	0.67	0.31	0.23	0.22	0.37	-0.01	0.12	0.42	0.33	-0.52	0.72		0.17	-0.31	0.32	0.41
Net Invested Capital	0.66	0.71	-0.08	-0.36	-0.06	0.73	-0.09	0.51	-0.03	0.15	-0.19	0.3	0.07	0.79	0.77	-0.14	0.48	0.17		-0.36	0.92	0.73
Long Term Investments	-0.53	-0.57	-0.03	0.5	0.13	-0.6	-0.55	-0.68	0.16	0.04	0.13	0.04	0.13	-0.67	-0.54	0.16	-0.25	-0.31	-0.36		-0.42	-0.5
Net Working Capital	0.67	0.74	0.02	-0.64	-0.19	0.78	0.09	0.53	-0.17	-0.15	-0.24	0.09	-0.14	0.86	0.85	-0.27	0.73	0.32	0.92	-0.42		0.92
Capital Stock	0.61	0.69	0.07	-0.8	-0.27	0.73	0.23	0.56	-0.3	-0.31	-0.25	-0.05	-0.27	0.82	0.8	-0.34	0.8	0.41	0.73	-0.5	0.92

Click cells to compare fundamentals

Funds with most asset allocated to stocks can be subclassified into many different categories such as market capitalization or investment style.

Competition

Predict Celldex Therapeutics

According to the company disclosure, Celldex Therapeutics has an Equity Positions Weight of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Piotroski F Score Now

Piotroski F Score

Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals

All Next

Launch Module

Celldex Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Celldex Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Celldex Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Celldex Fundamentals

	Return On Equity	-0.3
	Return On Asset	-0.2
	Operating Margin	(16.34) %
	Current Valuation	931.57 M
	Shares Outstanding	66.34 M
	Shares Owned By Institutions	100.00 %
	Number Of Shares Shorted	7.31 M
	Price To Earning	(2.21) X
	Price To Book	2.14 X
	Price To Sales	168.85 X
	Revenue	6.88 M
	Gross Profit	(79.9 M)
	EBITDA	(139.03 M)
	Net Income	(141.43 M)
	Cash And Equivalents	356.82 M
	Cash Per Share	7.63 X
	Total Debt	2.54 M
	Debt To Equity	0.01 %
	Current Ratio	12.29 X
	Book Value Per Share	11.85 X
	Cash Flow From Operations	(107.29 M)
	Short Ratio	6.61 X
	Earnings Per Share	(2.58) X
	Target Price	67.1
	Number Of Employees	160
	Beta	1.59
	Market Capitalization	1.68 B
	Total Asset	465.63 M
	Retained Earnings	(1.4 B)
	Working Capital	400.57 M
	Current Asset	294.94 M
	Current Liabilities	30.24 M
	Net Asset	465.63 M

About Celldex Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Celldex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC